Loading
A parallel classification to the WHO 2022 edition from an international expert group, which among other changes creates an MDS/AML category for 10 to 19 percent blasts and gives TP53-mutated disease its own entities.
Classification of myeloid neoplasms and acute leukaemias integrating morphology, clinical features and genomics, produced by the International Consensus Classification group, with new categories for MDS/AML, TP53-mutated myeloid neoplasms and genetically defined AML subtypes at lower blast thresholds.
Trial eligibility and risk stratification in AML and MDS often refer to this classification alongside the WHO edition; the two overlap heavily but not completely.